Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
Description | Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3. |
Targets&IC50 | JAK2:5.0 nM, JAK1:3.9 nM, Tyk2:4.8 nM, JAK3:0.7 nM |
In vitro | ASP015K suppresses the IL-2-induced proliferation of human T cells with greater potency than EPO-induced proliferation of human erythroleukemia cells. In human whole blood, ASP015K inhibits STAT5 phosphorylation (pSTAT5). [1] |
In vivo | In the rat AIA model, ASP015K (p.o.) significantly decreases paw swelling and ankle bone destruction score. [1] |
Synonyms | JNJ-54781532, ASP015K |
Molecular Weight | 326.39 |
Formula | C18H22N4O2 |
CAS No. | 944118-01-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
H2O: <1 mg/mL
Ethanol: <1 mg/mL
DMSO: 60 mg/mL (183.8 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Peficitinib 944118-01-8 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors Tyrosine Kinases JAK Janus kinase lymphocytes JNJ-54781532 JNJ 54781532 JNJ54781532 Inhibitor rheumatoid arthritis inhibit IL-2 splenocytes ASP015K inhibitor